Get the Daily Brief
Latest Biotech News
Glioblastoma and Gasdermin E Pyroptosis Resistance
New research challenges the established role of Gasdermin E (GSDME) as a pyroptosis executor by demonstrating its paradoxical contribution to glioblastoma’s resistance to pyroptosis and tumor...
AI Platform Diagnoses Vocal Cord Paralysis Severity
Researchers have introduced an AI-powered diagnostic tool using convolutional neural networks (CNNs) with Mel-spectrogram audio analysis to automatically assess the severity of unilateral vocal...
Novo Nordisk Amylin Obesity Drug Dosing Questions
Novo Nordisk’s novel amylin-targeting obesity drug amycretin showed substantial weight loss in phase 1/2 trials, achieving up to 24.3% body weight reduction at the highest dose. However, similar...
Vertex Diabetes Stem Cell Therapy Results
Vertex Pharmaceuticals reported that 10 of 12 type 1 diabetes patients treated with their investigational off-the-shelf stem cell therapy, zimislecel, maintained insulin independence for at least...
FDA Regulatory Shakeup and Review Acceleration Program
The U.S. FDA has undertaken significant leadership realignments within the Center for Biologics Evaluation and Research, including the removal of senior executives to align management with...
Overcoming Cancer Drug Resistance Through Genetic Barcoding
A novel method employing genetic barcoding has been developed to track cancer cell adaptation and resistance evolution under drug pressure dynamically. This technique enables the precise...
CHEK2 as an Immunotherapy Target in Solid Tumors
Emerging evidence reveals the tumor suppressor gene CHEK2 not only functions in DNA repair but also modulates anti-tumor immunity in solid cancers. CHEK2 deficiency disrupts homologous...
Novartis Ramps US FDA Review Speed with Pilot Program
The US Food and Drug Administration (FDA) has introduced a new pilot commissioner’s national priority voucher program aimed at accelerating review times for biotech companies. Announced alongside...
Vertex Diabetes Cell Therapy Drops Insulin for 10 Patients
Vertex Pharmaceuticals has demonstrated promising clinical data for its off-the-shelf stem cell therapy aimed at type 1 diabetes, with 10 out of 12 patients stopping insulin injections a year...
Prothena Cuts Staff by 63% After Amyloidosis Drug Setback
Prothena, an Irish biotech focused on protein dysregulation diseases, is undertaking a major workforce reduction, laying off 63% of employees following the failure of its phase 3 amyloidosis drug...
CHEK2 Deficiency Enhances Immunotherapy Response in Solid Tumors
A novel analysis published in Oncotarget highlights the immunomodulatory role of CHEK2 gene deficiency in solid tumors, extending beyond its classical DNA repair functions. Loss of CHEK2 impairs...
Breakthrough in Nanoparticle Drug Delivery Enhances Stability and Load
Researchers at Xi’an Jiaotong-Liverpool University and Nanjing University have developed a novel nanoparticle drug delivery system combining PLGA polymer with albumin protein, yielding...
New Artificial Intelligence Model Detects Parkinson’s via Speech
An advanced semi-supervised fusion architecture leveraging speech embeddings has been developed to detect Parkinson's disease with high sensitivity. This AI system analyzes nuanced vocal features...
Signs of Immune Evasion in H5N1 Virus Highlighted by AI Study
A University of North Carolina study using AlphaFold 3 protein structure predictions combined with AI and physics-based modeling reveals that the H5N1 avian influenza virus has evolved mutations...
Novo Nordisk’s Amylin Drug Raises Dose and Safety Questions
Data from Novo Nordisk's Phase 1/2 trial of the obesity treatment amycretin reveal substantial weight loss gains but atypical dose-response curves and notable adverse event rates. At the American...
Michael J. Fox Foundation Launches T2T Program for Parkinson’s Targets
The Michael J. Fox Foundation (MJFF) introduced the Targets to Therapies (T2T) initiative, focusing on accelerating validation and tool development for 21 prioritized molecular targets in...
European CHMP Backs Five New Medicines, Reviews Eli Lilly Alzheimer’s Drug
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the authorization of five new drugs, four of which already hold US approvals. Additionally, CHMP...
FDA Launches Pilot Program to Accelerate Biotech Reviews
The U.S. Food and Drug Administration (FDA) has unveiled a new pilot program granting biotechnology companies a priority voucher that shortens drug review times by one to two months, aiming to...
Vertex’s Stem Cell Therapy Cuts Insulin Use in Type 1 Diabetes
Vertex Pharmaceuticals presented promising data from clinical trials of its off-the-shelf stem cell therapy, zimislecel (formerly VX-880), for type 1 diabetes. The Phase 1/2 study showed that 10...
Novo Nordisk’s Amylin Drug Raises Dosing and Side Effect Queries
Novo Nordisk’s amycretin, a next-generation amylin analog for obesity, demonstrated significant weight loss in a Phase 1/2 trial, with the highest 60 mg dose yielding average 24.3% weight...